Endometrial cancer
P Morice, A Leary, C Creutzberg, N Abu-Rustum… - The Lancet, 2016 - thelancet.com
Endometrial cancer is the most common gynaecological tumour in developed countries,
and its incidence is increasing. The most frequently occurring histological subtype is …
and its incidence is increasing. The most frequently occurring histological subtype is …
[HTML][HTML] European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
…, D Kolencik, R Kristeleit, A Kryzhanivska, A Leary… - Annals of …, 2022 - Elsevier
Background Homologous recombination repair (HRR) enables fault-free repair of double-stranded
DNA breaks. HRR deficiency is predicted to occur in around half of high-grade …
DNA breaks. HRR deficiency is predicted to occur in around half of high-grade …
[HTML][HTML] The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
B Cheaib, A Auguste, A Leary - Chinese journal of cancer, 2015 - Springer
The phosphatidylinositol 3 kinase (PI3K) pathway is frequently altered in cancer, including
ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging …
ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging …
[HTML][HTML] Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
…, A Lisyanskaya, A Floquet, A Leary… - … England Journal of …, 2018 - Mass Medical Soc
Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
…, E Mann, SH Kaufmann, A Floquet, A Leary… - The lancet …, 2017 - thelancet.com
Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …
Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine.
…, CR Wood, RM O'Hara Jr, AC Leary… - Proceedings of the …, 1990 - National Acad Sciences
Hematopoiesis occurs in close association with a complex network of cells loosely termed
the hematopoietic microenvironment. Analysis of the mechanisms of microenvironmental …
the hematopoietic microenvironment. Analysis of the mechanisms of microenvironmental …
Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins
…, JAS Witek, PA Temple, KM Wilkens, AC Leary… - Science, 1985 - science.org
Clones of complementary DNA encoding the human lymphokine known as granulocyte-macrophage
colony-stimulating factor (GM-CSF) were isolated by means of a mammalian cell (…
colony-stimulating factor (GM-CSF) were isolated by means of a mammalian cell (…
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
…, LR Mileshkin, HJ Mackay, A Leary… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study
…, L Xu, S Zeigenfuss, SK Pruitt, A Leary - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket
study investigating the antitumor activity and safety of pembrolizumab in multiple cancer …
study investigating the antitumor activity and safety of pembrolizumab in multiple cancer …
Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG …
…, A Lisyanskaya, A Floquet, A Leary… - Obstetrical & …, 2023 - journals.lww.com
Because of nonspecific symptoms at disease presentation and inadequate screening methods,
ovarian cancer is often advanced at the time of diagnosis results in a 10-year survival of …
ovarian cancer is often advanced at the time of diagnosis results in a 10-year survival of …